CA1214101A - Preparation utilisee dans le diagnostic des infections a chlamydia - Google Patents

Preparation utilisee dans le diagnostic des infections a chlamydia

Info

Publication number: CA1214101A
Authority: CA; Canada
Prior art keywords: lipopolysaccharide; chlamydial; group; kdo; gram negative
Prior art date: 1983-05-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000429318A

Other languages

English (en)

Inventor

Pirjo Makela

Marjatta Nurminen-Kalliokoski

Maija Leinonen

Pekka Saikku

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Orion Oyj

Original Assignee

Orion Oyj

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-05-31

Filing date

1983-05-31

Publication date

1986-11-18

1983-05-31 Application filed by Orion Oyj filed Critical Orion Oyj

1983-05-31 Priority to CA000429318A priority Critical patent/CA1214101A/fr

1986-11-18 Application granted granted Critical

1986-11-18 Publication of CA1214101A publication Critical patent/CA1214101A/fr

Status Expired legal-status Critical Current

Links

238000002360 preparation method Methods 0.000 title claims abstract description 37
206010061041 Chlamydial infection Diseases 0.000 title claims abstract description 16
238000003745 diagnosis Methods 0.000 title claims description 18
239000002158 endotoxin Substances 0.000 claims abstract description 75
229920006008 lipopolysaccharide Polymers 0.000 claims abstract description 65
239000000427 antigen Substances 0.000 claims abstract description 50
102000036639 antigens Human genes 0.000 claims abstract description 50
108091007433 antigens Proteins 0.000 claims abstract description 50
238000000034 method Methods 0.000 claims abstract description 50
241000894006 Bacteria Species 0.000 claims abstract description 47
241000498849 Chlamydiales Species 0.000 claims abstract description 37
230000000405 serological effect Effects 0.000 claims abstract description 16
238000004519 manufacturing process Methods 0.000 claims abstract description 10
241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 claims abstract description 9
230000003053 immunization Effects 0.000 claims abstract description 9
230000001900 immune effect Effects 0.000 claims abstract description 8
238000002649 immunization Methods 0.000 claims abstract description 7
241000588724 Escherichia coli Species 0.000 claims abstract description 3
241000588770 Proteus mirabilis Species 0.000 claims abstract description 3
241000606161 Chlamydia Species 0.000 claims description 31
KYQCXUMVJGMDNG-SHUUEZRQSA-N keto-3-deoxy-D-manno-octulosonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CC(=O)C(O)=O KYQCXUMVJGMDNG-SHUUEZRQSA-N 0.000 claims description 20
HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims description 18
229930186217 Glycolipid Natural products 0.000 claims description 18
238000012360 testing method Methods 0.000 claims description 16
230000006872 improvement Effects 0.000 claims description 14
210000002966 serum Anatomy 0.000 claims description 14
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims description 12
239000000306 component Substances 0.000 claims description 11
239000008358 core component Substances 0.000 claims description 11
229920001282 polysaccharide Polymers 0.000 claims description 10
239000005017 polysaccharide Substances 0.000 claims description 10
239000003513 alkali Substances 0.000 claims description 9
150000004676 glycans Chemical class 0.000 claims description 7
230000001580 bacterial effect Effects 0.000 claims description 6
238000003018 immunoassay Methods 0.000 claims description 6
239000007924 injection Substances 0.000 claims description 6
238000002347 injection Methods 0.000 claims description 6
241001465754 Metazoa Species 0.000 claims description 5
125000004432 carbon atom Chemical group C* 0.000 claims description 5
235000014113 dietary fatty acids Nutrition 0.000 claims description 5
229930195729 fatty acid Natural products 0.000 claims description 5
239000000194 fatty acid Substances 0.000 claims description 5
150000004665 fatty acids Chemical class 0.000 claims description 5
239000000203 mixture Substances 0.000 claims description 5
102000004190 Enzymes Human genes 0.000 claims description 4
108090000790 Enzymes Proteins 0.000 claims description 4
230000000295 complement effect Effects 0.000 claims description 4
238000010166 immunofluorescence Methods 0.000 claims description 4
150000002772 monosaccharides Chemical class 0.000 claims description 4
230000008569 process Effects 0.000 claims description 4
238000003127 radioimmunoassay Methods 0.000 claims description 4
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 3
-1 KDO trisaccharide Chemical class 0.000 claims description 3
PLBVFNYORPRCME-YMDUGQBDSA-N OP(O)(O)=O.OC[C@](O)(N)[C@@H](O)[C@H](O)C=O Chemical compound OP(O)(O)=O.OC[C@](O)(N)[C@@H](O)[C@H](O)C=O PLBVFNYORPRCME-YMDUGQBDSA-N 0.000 claims description 3
241000607142 Salmonella Species 0.000 claims description 3
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 3
229960002442 glucosamine Drugs 0.000 claims description 3
NNLZBVFSCVTSLA-XMABDTGBSA-N (4r,5r,6r)-6-[(1r)-1,2-dihydroxyethyl]-2,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound OC[C@@H](O)[C@H]1OC(O)(C(O)=O)C[C@@H](O)[C@H]1O NNLZBVFSCVTSLA-XMABDTGBSA-N 0.000 claims description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical group OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims description 2
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
125000003277 amino group Chemical group 0.000 claims description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
229910052799 carbon Inorganic materials 0.000 claims description 2
229930182830 galactose Natural products 0.000 claims description 2
239000008103 glucose Substances 0.000 claims description 2
150000002386 heptoses Chemical class 0.000 claims description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
238000000760 immunoelectrophoresis Methods 0.000 claims description 2
238000001514 detection method Methods 0.000 claims 2
150000002016 disaccharides Chemical group 0.000 claims 1
150000002302 glucosamines Chemical class 0.000 claims 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 abstract description 5
230000005180 public health Effects 0.000 abstract description 5
230000035931 haemagglutination Effects 0.000 abstract description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 10
238000002955 isolation Methods 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 5
150000002500 ions Chemical class 0.000 description 5
208000000143 urethritis Diseases 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
229920001817 Agar Polymers 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
239000004141 Sodium laurylsulphate Substances 0.000 description 3
239000008272 agar Substances 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
230000008859 change Effects 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
235000013601 eggs Nutrition 0.000 description 3
239000002609 medium Substances 0.000 description 3
235000019333 sodium laurylsulphate Nutrition 0.000 description 3
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
230000000721 bacterilogical effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
238000002405 diagnostic procedure Methods 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
239000003208 petroleum Substances 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
241000894007 species Species 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000011282 treatment Methods 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
206010003267 Arthritis reactive Diseases 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
241000606153 Chlamydia trachomatis Species 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 1
206010018910 Haemolysis Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
AAXCQFOXUJMCCW-PETQGJDISA-N LPS core Chemical compound O([C@H]1[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H]([C@@H]([C@@H](CO[C@]2(O[C@@H]([C@@H](OC3[C@H]([C@@H](OC4[C@H]([C@@H](OC5[C@@H]([C@@H](O[C@@H]6[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O6)OC6[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O6)NC(C)=O)[C@H](O)[C@@H](CO[C@@H]6[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O6)O)O5)O)[C@H](O)[C@@H]([C@@H](O)COC5[C@H]([C@@H](O)[C@H](OP(O)(O)=O)[C@@H]([C@@H](O)CO)O5)O)O4)O)[C@H](OP(O)(=O)OP(O)(=O)OCCN)[C@@H]([C@@H](O)CO)O3)O)[C@H](O[C@]3(O[C@@H]([C@@H](O)[C@H](O[C@]4(O[C@@H]([C@@H](O)[C@H](OP(O)(=O)OCCN)C4)[C@@H](O)CO)C(O)=O)C3)[C@@H](O)CO)C(O)=O)C2)[C@@H](O)CO)C(O)=O)O1)OP(O)(O)=O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C[C@H]1O[C@H](OP(O)(O)=O)[C@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H]1O AAXCQFOXUJMCCW-PETQGJDISA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000035539 Ovarian infection Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
241000588769 Proteus <enterobacteria> Species 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
206010000210 abortion Diseases 0.000 description 1
231100000176 abortion Toxicity 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000001358 anti-chlamydial effect Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
108010065183 antilipopolysaccharide antibodies Proteins 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
238000009835 boiling Methods 0.000 description 1
201000000902 chlamydia Diseases 0.000 description 1
229940038705 chlamydia trachomatis Drugs 0.000 description 1
208000012538 chlamydia trachomatis infectious disease Diseases 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000037029 cross reaction Effects 0.000 description 1
238000012136 culture method Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
201000010099 disease Diseases 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
230000036541 health Effects 0.000 description 1
230000008588 hemolysis Effects 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
238000009630 liquid culture Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
244000045947 parasite Species 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000002574 poison Substances 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
208000002574 reactive arthritis Diseases 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
150000004043 trisaccharides Chemical class 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
230000003612 virological effect Effects 0.000 description 1

Landscapes

Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CA000429318A 1983-05-31 1983-05-31 Preparation utilisee dans le diagnostic des infections a chlamydia Expired CA1214101A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000429318A CA1214101A (fr)	1983-05-31	1983-05-31	Preparation utilisee dans le diagnostic des infections a chlamydia

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA000429318A CA1214101A (fr)	1983-05-31	1983-05-31	Preparation utilisee dans le diagnostic des infections a chlamydia

Publications (1)

Publication Number	Publication Date
CA1214101A true CA1214101A (fr)	1986-11-18

Family

ID=4125364

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000429318A Expired CA1214101A (fr)	1983-05-31	1983-05-31	Preparation utilisee dans le diagnostic des infections a chlamydia

Country Status (1)

Country	Link
CA (1)	CA1214101A (fr)

1983
- 1983-05-31 CA CA000429318A patent/CA1214101A/fr not_active Expired

Legal Events

Date	Code	Title	Description
2003-11-18	MKEX	Expiry

Publication	Publication Date	Title
CA1230551A (fr)	1987-12-22	Preparation utilisee pour le diagnostic des infections a chlamydia
Mandrell et al.	1991	Endogenous sialylation of the lipooligosaccharides of Neisseria meningitidis
US4683196A (en)	1987-07-28	Method and materials for the identification of lipopolysaccharide producing microorganisms
Brade et al.	1987	The immunogenicity and antigenicity of lipid A are influenced by its physicochemical state and environment
Brade et al.	1986	Chemical, biological, and immunochemical properties of the Chlamydia psittaci lipopolysaccharide
US20080020002A1 (en)	2008-01-24	METHOD OF PRODUCING MENINGOCOCCAL MENINGITIS VACCINE FOR NEISSERIA MENINGITIDIS SERO TYPES A,C,Y, and W-135
Carlsson et al.	1975	Quantitation of Salmonella O-antibodies in human sera by enzyme-linked immunosorbent assay (ELISA)
Räisänen et al.	1980	Serological diagnosis of Mycoplasma pneumoniae infection by enzyme immunoassay.
Kim et al.	1994	Meningococcal group A lipooligosaccharides (LOS): preliminary structural studies and characterization of serotype-associated and conserved LOS epitopes
Tsang et al.	1987	A murine monoclonal antibody specific for the outer core oligosaccharide of Salmonella lipopolysaccharide
US3636192A (en)	1972-01-18	Meningococcal polysaccharide vaccines
Wuhrer et al.	1999	Immunochemical characterisation of Schistosoma mansoni glycolipid antigens
WO1985002685A1 (fr)	1985-06-20	Procede et substances permettant l'identification de micro-organismes produisant du lipopolysaccharide
Maeland et al.	1971	IMMUNOCHEMICAL INVESTIGATIONS ON NEISSERIA GONORRHOEAE ENDOTOXIN: 2. Serological Multispecificity and Other Properties of Phenol‐Water Preparations
CA1214101A (fr)	1986-11-18	Preparation utilisee dans le diagnostic des infections a chlamydia
US5653986A (en)	1997-08-05	Vibrio cholerae bengal serogroup-O139 capsular polysaccharide and protein conjugates thereof
US4609630A (en)	1986-09-02	Method for improving the specificity of immunoassays
Lindberg et al.	1988	Shigella flexneri O-antigen specific enzyme immunoassay: lipopolysaccharides and synthetic glycoconjugates as antigens
Brennan	1986	The carbohydrate-containing antigens of Mycobacterium leprae
US20040137554A1 (en)	2004-07-15	Diagnosis and treatment of bacterial infections
Nalbantsoy et al.	2010	Isolation and purification of O and H antigens from Salmonella Enteritidis as diagnostic tool
EP0253912B1 (fr)	1991-02-06	Oligosaccharides, leur procédé de préparation et leur utilisation
Raichvarg et al.	1979	Chemical composition and biological activities of a phenol-water extract from Haemophilus influenzae type a
Penaredondo et al.	1988	Production and partial characterization of monoclonal antibodies to Pasteurella haemolytica A1 capsular polysaccharide and lipopolysaccharide
Mertsola et al.	1990	Specific detection of Haemophilus influenzae type b lipooligosaccharide by immunoassay